Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial shows reduced cardiovascular risk in patients with clonal hematopoiesis, indicating potential therapeutic targets.
Key Points
- This research aims to investigate whether genetic deficiencies in IL-6 signaling can lower cardiovascular risk in individuals with clonal hematopoiesis (CHIP).
- Examined the association between clonal hematopoiesis and cardiovascular disease risk
- Utilized genetic analysis to identify IL-6 signaling deficiencies among CHIP carriers
- Explored the impact of reduced IL-6 signaling on cardiovascular health outcomes.
- CHIP is associated with increased risk of incident cardiovascular disease (CVD)
- In CHIP carriers with genetic IL-6 signaling deficiency, the risk of developing CVD was significantly reduced (P=0.036).
Cite This Study
Bick et al. (2019) studied this question.